313490-19-6

Upstream product

• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 
• 143323-49-3 (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate 
• 27460-85-1 N-(tert-butoxycarbonyl)-D-(4-hydroxyphenyl)glycine 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 22818-40-2 D-4-hydroxyphenylglycine 
• 24424-99-5 di-tert-butyl dicarbonate 

Downstream Products

• 1232400-58-6 methyl N-tert-butoxycarbonyl-4-(3-thienyl)-D-phenylglycinate 
• 943731-26-8 C₁₅H₁₈N₂O₄ 
• 843673-72-3 trifluoromethanesulfonic acid 4-((R)-1-tert-butoxycarbonylamino-2-hydroxyethyl)phenyl ester 

Relevant academic research and scientific papers

Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as α-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies

Novel α-mannosidase inhibitors of the type (2R,3R,4S)-2-({[(1R)-2-hydroxy-1-arylethyl]amino}methyl)pyrrolidine-3,4-diol have been prepared and assayed for their anticancer activities. Compound 30 with the aryl group = 4-trifluoromethylbiphenyl inhibits the proliferation of primary cells and cell lines of different origins, irrespective of Bcl-2 expression levels, inducing a G2/Mcell cycle arrest and by modification of genes involved in cell cycle progression and survival.

Derivatives of Dihydroxypyrrolidine as Anti-Cancer Compounds

The present invention relates to derivatives of dihydroxypyrrolidine useful in the treatment of cancer. The invention further relates to a process for making the compounds. The compounds are inhibitors of α mannosidase, and possibly, also inhibit nicotina

Suppression of racemization in the carbonylation of amino acid-derived aryl triflates

The carbonylation of enantiopure phenylglycine-derived aryl triflates was achieved to afford 4-carboxyphenylglycine analogs with high enantiomeric excesses (88 to >99% ee). Amide analogs of phenylglycine were well-tolerated in the hydroxy- and methoxycarbonylation processes, providing efficient access to benzoic acid and ester building blocks. The % ee of the product was dependent on the relative steric bulk of both the amino acid substrate and the requisite amine base, with iPr2NEt proving optimal in minimizing product racemization.

Substituted bis-amide metalloprotease inhibitors

This invention relates to substituted bis-amide pyrimidine compounds of Formula (I), which are useful for the treatment of metalloprotease mediated diseases, in particular MMP-13 related diseases.